SEC Form 4 · accession 0001237899-15-000036
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Alexander Ingram
Director
Period of report
May 22, 2015
Accepted (ET)
May 27, 2015 · 4:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 22, 2015 | M | 6,667 | $293.53 | A | 6,667 | D | |
| Common Stock | May 22, 2015 | F | 3,788 | $516.48 | D | 2,879 | D | |
| Common StockF1 | May 27, 2015 | S | 1,379 | $513.39 | D | 1,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $293.53 | May 22, 2015 | M | 6,667 | D | — | Apr 4, 2024 | Common Stock | 6,667 | 13,333 | D |
Explanation of responses
- F1Represents volume-weighted average price of sales of 1,379 shares of Company stock on May 27, 2015 at prices ranging from $513.14 to $513.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 27, 2015 at each separate price.
- F2The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.